— Endo International plc (NASDAQ: ENDP) reported its fourth-quarter 2019 adjusted earnings of $0.74 per share versus $0.57 per share expected.
— Total revenues declined by 3% to $764.8 million versus $731.43 million expected. This was due to competitive pressures in the Generic Pharmaceuticals segment and the Established Products portfolio of the Branded Pharmaceuticals segment.
— Branded Pharmaceuticals revenues decreased by 2% due to the ongoing generic competition in the Established Products portfolio.
— Specialty Products revenues increased by 15% primarily driven by the continued strong performance of Xiaflex. The demand growth in both the Peyronie’s Disease and Dupuytren’s Contracture indications drove Xiaflex sales higher.
— Revenues of the Sterile Injectables segment increased by 10% to $285 million. This was driven by the continued strong growth of Vasostrict and Adrenalin.
— Generic Pharmaceuticals revenues dropped by 14% due to the continued competitive pressure on commoditized generic products. The ongoing generic competition also hurt the International Pharmaceuticals revenue, which fell by 16%.
— Looking ahead into the full year 2020, the company expects total revenue of $2.72-2.92 billion and adjusted EPS from continuing operations of $2.15-2.40. The consensus estimates EPS of $2.25 on revenue of $2.90 billion.
Nvidia Corporation (NASDAQ: NVDA) Wednesday said its fourth-quarter revenues and profit increased in double-digits amid elevated demand. The results also topped the Street view, driving the stock higher during the
Nutanix (NASDAQ: NTNX) reported second quarter 2021 earnings results today. Total revenue remained flat at $346.4 million compared to the same period a year ago. GAAP net loss was $287.3
Shares of Macy’s Inc. (NYSE: M) were down 2.7% in morning trade on Wednesday. The stock has gained 37% since the beginning of the year. A day ago, the retailer